Wayshine Biopharm is the lead sponsor of 3 current clinical trials in our China and USA registers. 3 are recruiting patients now. The most common phase is Phase 1/2. The drugs named most often in its trials are WSD0922-FU, Osimertinib and Tagrisso. The most-studied condition is Non Small Cell Lung Cancer.
| Study | Phase | Status | Start | Registers |
|---|---|---|---|---|
|
A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer
NCT06868485 · Non Small Cell Lung Cancer
Drug: WSD0922-FU |
Phase 2 | Recruiting | 2025-08 | USA, China |
|
A Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC
NCT07206498 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer (NSCLC)
|
Phase 1/2 | Recruiting | 2025-10 | China |
|
A Study to Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advanced Non-small Cell Lung Cancer
NCT06631989 · ClinicalTrials.gov ↗ · EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer
Drug: WSD0922-FU |
Phase 1/2 | Recruiting | 2024-09 | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 3 | 3 |
| Clinical trials in USA | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
Sponsors with the most current trials registered for this condition.
Wayshine Biopharm is the lead sponsor of 3 current trials on ClinicalTrials.gov in our China and USA registers, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 3 of its 3 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Its current trials name 3 drugs and biologicals as interventions. The most frequent are WSD0922-FU (3), Osimertinib (1) and Tagrisso (1). The number in brackets is how many of its trials name each drug.
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.